Orlin Pavlov, Mirchev Nikolay, Obersheimer Jens and Behr Robert
In our case report, we discuss a patient, who underwent a dual antiplatelet therapy as a secondary prevention of stroke. To our knowledge, there are no other cases in the literature reviews about pituitary haemorrhage on dual antiplatetelet therapy. The 7th most common reason for intrapituitary haemorrhage is aspirin. However, the risk for bleeding was not considered when a dual therapy was administered.
The patients, who have suffered a stroke, need a suitable secondary stroke prophylaxis. The dual therapy has shown advantages over the monotherapy with aspirin or with clopidogrel. The personal approach to every patient, who has suffered a stroke, has to be taken. The pituitary adenoma can increase the risk for intracranial bleeding, when a dual therapy is used as a second stroke prophylaxis.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 